Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesIFCT-0401 trial: A phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype
Journal of Thoracic Oncology, 09/03/09
Cadranel J et al. – Gefitinib combines efficacy with low toxicity and is suitable as a first-line treatment of advanced ADC-BAC, particularly in patients with non-mucinous BAC subtype.
Methods- Chemotherapy-naive patients (n = 88) with advanced ADC-BAC were treated with 250 mg/d of gefitinib
- Clinical and disease characteristics that conferred a favorable prognosis under gefitinib were also analyzed
- Disease control was achieved in 25 patients (29.4%); 11 patients (12.9%) had partial response and 14 (16.4%) had stable disease.
- Median PFS was 2.9 mos and median OS was 13.2 mos
- Never smokers, patients with low respiratory symptoms score, occurrence of cutaneous rash, and nonmucinous ADC-BAC subtype were associated with increased probability of disease control
- Nonmucinous ADC-BAC was associated with increased PFS and OS at 3 years
- Patients with non-mucinous BAC had longer OS and PFS compared with patients with other ADC-BAC variants; median PFS for non-mucinous BAC was 11.3 mos, whereas it was 2.6 mos for mucinous BAC
- Toxicity was low, with dermatologic problems, diarrhea, and nausea being the most common adverse events
Related Articles
Increased risk of oesophageal adenocarcinoma among upstream petroleum workers
Occupational and Environmental Medicine, 11/06/09
Relevance Score: 89%
Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation
Molecular Carcinogenesis, 10/27/09
Relevance Score: 88%
Use of EGFR/KRAS Mutation Testing To Define Clonal Relationships Among Multiple Lung Adenocarcinomas
Chest, 10/08/09
Relevance Score: 88%
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival
Clinical Cancer Research, 10/01/09
Relevance Score: 88%
Diagnostic Efficacy of PET/CT Plus Brain MR Imaging for Detection of Extrathoracic Metastases in Patients with Lung Adenocarcinoma
Journal of Korean Medical Science, 11/16/09
Relevance Score: 87%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma
Cancer Research, 12/10/09
Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 12/10/09
Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy
Anti-Cancer Drugs, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor